🇺🇸 FDA
Patent

US 12227584

Multivalent and multispecific OX40-binding fusion proteins

granted A61KA61K2039/505A61P

Quick answer

US patent 12227584 (Multivalent and multispecific OX40-binding fusion proteins) held by Inhibrx Biosciences, Inc. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx Biosciences, Inc.
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61P, A61P29/00, A61P35/00